Background Novel coronavirus disease 2019 (COVID-19) vaccine hesitancy is a barrier to
achieving herd immunity, and thus, a prominent public health concern. This study aimed to …

Kynurenic acid (KYNA) is an endogenous antagonist of N-methyl-D-aspartate and α7 nicotinic
acetylcholine receptors that is derived from astrocytes as part of the kynurenine pathway …

Currently available treatments have limited pro-cognitive effects for neuropsychiatric
disorders, such as schizophrenia, Parkinson's disease and Alzheimer's disease. The primary …

Cognitive impairment is a core symptom domain of schizophrenia. The effect of antipsychotics,
the cornerstone of treatment in schizophrenia, on this domain is not fully clear. There is …

Findings from neuroimaging studies in patients with schizophrenia suggest widespread
structural changes although the mechanisms through which these changes occur are currently …

Antipsychotic drugs are the mainstay in the treatment of schizophrenia. However, one-third
of patients do not show adequate improvement in positive symptoms with non-clozapine …

Background In terms of antipsychotic treatment response, patients with schizophrenia can
be classified into three groups: 1) treatment resistant to both non-clozapine (non-CLZ) …

Background Recent developments in neuroimaging have advanced the understanding of
biological mechanisms underlying schizophrenia. However, neuroimaging correlates of …

Adherence to antipsychotic medication is critical for the treatment of patients with schizophrenia.
Impaired insight into illness is one of the principal drivers of medication nonadherence, …

Importance Patients with late-life schizophrenia (LLS) are highly susceptible to antipsychotic
adverse effects. Treatment guidelines endorse lower antipsychotic doses. However, the …